Understanding pancreatic cancer subtypes and how a protein called PHF2 affects their growth
Epigenetic regulation of pancreatic cancer subtype identity and tumorigenesis by PHF2
['FUNDING_R01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11114003
This research explores how a protein called PHF2 influences the different types of pancreatic cancer and their ability to grow.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11114003 on ClinicalTrials.gov |
What this research studies
Pancreatic cancer has two main types, Classical and Basal-like, which help predict how patients might respond to treatment. We want to understand what controls these different cancer types. Our early work suggests that a protein called PHF2 plays a key role in the Classical type of pancreatic cancer, and when we turn it off, tumor growth is greatly reduced. This project will use human cancer cells and advanced mouse models to learn more about how PHF2 affects the cancer's genetic makeup and growth.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to benefit those diagnosed with pancreatic ductal adenocarcinoma, particularly those with the Classical subtype.
Not a fit: Patients with other types of cancer or those whose pancreatic cancer does not involve the PHF2 protein may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to identify and target specific pancreatic cancer subtypes, potentially improving treatment options for patients.
How similar studies have performed: Preliminary experiments have shown promising results in patient-derived cells and mouse models, indicating that targeting PHF2 can reduce tumor growth.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LISS, ANDREW — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: LISS, ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.